Clinical trials: Hyperlipidaemia
Hypercholesterolemia, Dyslipidemia
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin.
- Trial name
- NCT00309777
- Testing
- Pitavastatin, Simvastatin
- Where
- 42 sites in Finland, Italy and 3 more
- Volunteers
- 857 people
- Sponsor
- Kowa Research Europe
Hypercholesterolemia, Mixed Dyslipidemia
Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean Food and Drug Administration.
- Trial name
- NCT01228019
- Testing
- Niacin (+) laropiprant
- Volunteers
- 1,166 people
- Sponsor
- Merck Sharp & Dohme LLC
Severe Hypertriglyceridemia (sHTG)
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
- Trial name
- NCT03452228
- Testing
- evinacumab
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolemia
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
This study will evaluate the efficacy and safety and tolerability of 2 dose levels of MK-0653H in Japanese participants. The primary hypotheses are that the administration of MK-0653H is safe and tolerable and that MK-0653H is…
- Trial name
- NCT02741245
- Testing
- Ezetimibe 10 mg, Rosuvastatin 2.5 mg
- Volunteers
- 321 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
- Trial name
- NCT01342211
- Testing
- Statin, PF-04950615 (RN316), Satin
- Where
- 44 sites in United States, Canada
- Volunteers
- 93 people
- Sponsor
- Pfizer
Hyperlipidemia, Insulin Resistance
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Background: There is general agreement that statin-treatment of patients to lower plasma cholesterol levels can increase the incidence of type 2 diabetes mellitus (T2D) in some individuals1-5.
- Conditions
- Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
- Trial name
- NCT02437084
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Stanford University
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01811472
- Testing
- LCQ908
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Severe Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVE (NCT01242527)
- Testing
- omefas
- Where
- 68 sites in United States, Denmark and 5 more
- Volunteers
- 399 people
- Sponsor
- AstraZeneca
Diabetes, Hypertension
Pharmacy Home Adherence Reporting and Monitoring Outcomes Study
This study is a pilot test of an intervention that delivers timely diagnostic information about medication nonadherence to doctors, and then offers the services of clinical pharmacists to treat these nonadherence problems.
- Conditions
- Diabetes, Hypertension, Hypercholesterolemia
- Trial name
- PHARxMOS (NCT02306122)
- Testing
- Pharmacist calls patient unless physician cancels call, Patient nonadherence information sent to physician, Pharmacist calls patient if physician requests call
- Where
- United States
- Volunteers
- 2,697 people
- Sponsor
- Brown University
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells.
- Trial name
- NCT00025883
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypercholesterolemia With Concomitant Type 2 Diabetes
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid lowering effect and glucose metabolism in hypercholesterolemia patients with diabetes mellitus.
- Trial name
- LISTEN (NCT01544309)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- 133 sites in Japan
- Volunteers
- 1,049 people
- Sponsor
- Listen Trial Group
Homozygous Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
The primary objective of this study is to evaluate the safety and tolerability of 4 doses of lomitapide (AEGR-733; BMS-201038) given as an initial low dose and then escalated through an additional 3 dose levels over a 16-week…
- Trial name
- NCT01556906
- Testing
- Lomitapide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Hypertension, Diabetes
Improving the Quality of Patient Care by Using a Clinical Expert System.
Aim: To investigate the quality of history taking by physician and computer-based system. Patients: 100 inpatients presenting at the RBK for the first time and treated in the departments of nephrology and cardiology.
- Conditions
- Hypertension, Diabetes, Hypercholesterolemia, Vasculitis
- Trial name
- CLEOS (NCT00430755)
- Testing
- Computer-assisted history, physician taken history, Computer-assisted history taking
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Hypertension, Arthritis
The Health Access and Recovery Peer Program
Individuals with serious mental illnesses (SMI) face high rates of medical comorbidity as well as challenges in managing these conditions.
- Conditions
- Hypertension, Arthritis, Coronary Artery Disease, Hepatitis
- Trial name
- HARP (NCT01725815)
- Testing
- HARP Intervention
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Hyperlipidemia
Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans
The hypothesis of this study is that the natural supplement Capros will decrease LDL levels, platelet aggregation, and serum concentrations of high sensitivity C-reactive protein in humans at risk for cardiovascular disease.
- Trial name
- Capros (NCT01858376)
- Testing
- Capros dietary supplement
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chandan K Sen
High Cholesterol
Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy
To determine the effects of policosanol on the cholesterol profile.
- Trial name
- NCT00510809
- Testing
- Policosanol, Policosanol Plus Already In Use Statin Therapy
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- James Backes, PharmD
Hypercholesterolemia, Myocardial Infarction
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40…
- Trial name
- NCT00202878
- Testing
- ezetimibe/simvastatin, simvastatin
- Volunteers
- 18,144 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.
- Trial name
- NCT03193047
- Testing
- bempedoic acid 180mg, evolocumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Esperion Therapeutics, Inc.